Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease

General Information

Description To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum in patients with Parkinson's disease.
Clinical trials phase Phases 1/2
Start date (estimated) 2018-08-01
Clinical feature
Label Parkinson's Disease
Link http://purl.obolibrary.org/obo/NCIT_C26845
Description A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.

Administrative Information

Other study identifiers
Name JPRN-UMIN000033564
Description UMIN Clinical Trials Registry (UMIN-CTR)
Source weblink https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038278
Regulatory body approval
Country
Public contact
Email neuroofc@kuhp.kyoto-u.ac.jp
First name Nobukatsu
Last name Sawamoto
Phone 075-751-3771
City Kyoto
Country
Japan
Address freetext 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507
Sponsors Kyoto University Hospital

Cell Line

Recruitment

Recruitment Status Recruiting
Estimated number of participants 7